Nav: Home

MDI Biological Laboratory providing incubator space to Coagulation Sciences LLC

January 25, 2017

BAR HARBOR, MAINE -- The MDI Biological Laboratory has announced that it is providing incubator space and associated scientific resources on its Bar Harbor campus to Coagulation Sciences LLC a Riverdale, N.Y- based development-stage medical device company.

Coagulation Sciences is developing the Multiple Coagulation Test System (MCTSTM) to help hospitals minimize or eliminate unnecessary blood transfusions and their associated risks by providing information to physicians to arrest bleeding more rapidly.

Michael Kagan, Coagulation Sciences' director of product development, an engineer and Maine resident, hopes to establish manufacturing of the MCTSTM instrument and its disposable test cartridge in Maine. Kagan chose the incubator space at the MDI Biological Laboratory because of its location and the institution's commitment to developing a vibrant life sciences ecosystem in Maine.

"Maine needs to develop a support system to promote innovation and commercialization if it is going to grow its life sciences sector," Kagan said. "An important step is providing the incubator space and expertise to move a product through its development cycle. The MDI Biological Laboratory has the core laboratory facilities, infrastructure and access to expertise that will help us take Coagulation Sciences to the next level. This space allows us to expand our development efforts without additional capital equipment."

Coagulation Sciences is representative of the trend toward personalized medicine, or the tailoring of treatments to individual needs. Current tests to determine if transfusions are needed are often non-specific or too slow to inform transfusion decisions. As a result, 30 to 40 percent of blood transfusions are unnecessary. The company's automated analytical system will have the ability to determine within minutes if a coagulation disorder is truly present, and, if so, help define the nature of the problem so that the physician can make an informed decision regarding treatment.

The MDI Biological Laboratory is an independent nonprofit biomedical research institution focused on basic discovery, translation of discoveries into technologies that improve human health and driving innovation and entrepreneurship through interdisciplinary research, training and network-building. The institution's research and development activities are focused on regenerative medicine and its scientists are pioneering new approaches to treating devastating diseases like heart attack.

"Our goal is to help create an entrepreneurial ecosystem that nurtures innovation in the life sciences by providing a collaborative environment and by connecting entrepreneurs with the resources they need," said Kevin Strange, Ph.D., MDI Biological Laboratory president. "Coagulation Sciences has developed a new technology that will revolutionize the way we manage blood transfusions and is seeking to manufacture its device in Maine. This is exactly the type of company we want to help support."

Other innovative startups that the MDI Biological Laboratory has helped to launch and/or grow include RockStep Solutions, a life sciences-based software development startup; Anecdata, a data collection web application for crowd sourcing scientific and other types of data; and Novo Biosciences, the institution's first for-profit spin-off, which is developing drug therapies to reactivate and stimulate the body's innate healing abilities.

"Maine's enviable quality of life, Yankee work ethic and outstanding research and educational institutions can be leveraged to build a thriving life sciences industry sector," Kagan says. "But continued investment in the infrastructure and resources to attract and support new life sciences enterprises and the development of a technology-focused entrepreneurial culture is critical."
The MDI Biological Laboratory, located in Bar Harbor, Maine, is an independent, non-profit biomedical research institution focused on increasing healthy lifespan and increasing our natural ability to repair and regenerate tissues damaged by injury or disease. The institution develops solutions to complex human health problems through research, education and ventures that transform discoveries into cures. For more information, please visit

Mount Desert Island Biological Laboratory

Related Blood Transfusions Articles:

Blood transfusions: Fresh red blood cells no better than older ones
Findings from the ABC-PICU study on critically ill children may alter policies at hospitals where fresh red cells are preferentially used.
Fresh red blood cell transfusions do not help critically ill children more than older cells
Researchers have found that transfusions using fresh red blood cells -- cells that have spent seven days or less in storage -- are no more beneficial than older red blood cells in reducing the risk of organ failure or death in critically ill children.
How high levels of blood fat cause inflammation and damage kidneys and blood vessels
Viral and bacterial infections are not the only causes of inflammation of body tissue.
Giving trauma patients blood pressure stabilizing hormone cuts transfusions by half
Giving trauma patients with severe blood loss the hormone arginine vasopressin (AVP) cut the volume of blood products required to stabilize them by half, according to results of a new, first-of-its-kind clinical trial from Penn Medicine.
Of mice and babies: New mouse model links transfusions to deadly infant digestive disease
Physicians have long suspected that red blood cell transfusions given to premature infants with anemia may put them in danger of developing a potentially lethal inflammatory disease of the intestines.
Postpartum transfusions on the rise, carry greater risk of adverse events
Women who receive a blood transfusion after giving birth are twice as likely to have an adverse reaction related to the procedure, such as fever, respiratory distress, or hemolysis (destruction of red blood cells), compared with non-pregnant women receiving the same care, according to a new study published today in Blood Advances.
Impeding white blood cells in antiphospholipid syndrome reduced blood clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.
Transfusions with older blood linked to adverse events, death, new study finds
Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours, according to a new study in Annals of Emergency Medicine.
Blood management program safely reduces transfusions in orthopedic patients
A patient blood management program designed to limit the amount of transfused blood orthopedic patients undergoing common surgeries such as hip and knee replacement receive was associated with fewer transfusions, reduced blood use and improved outcomes, reports a study published in the Online First edition of Anesthesiology, the peer-reviewed journal of the American Society of Anesthesiologists (ASA).
Turbulence allows clinical-scale platelet production for transfusions
Turbulence is a critical physical factor that promotes the large-scale production of functional platelets from human induced pluripotent stem cells, researchers in Japan report July 12 in the journal Cell.
More Blood Transfusions News and Blood Transfusions Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at